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Abstract: Plasmodium falciparum and P. vivax malaria parasites are now resistant, or 
showing signs of resistance, to most drugs used in therapy. Novel chemical entities that 
exhibit new mechanisms of antiplasmodial action are needed. New antimalarials that block 
transmission of Plasmodium spp. from humans to Anopheles mosquito vectors are key to 
OPEN ACCESS
Molecules 2013, 18 9220 
 
 
malaria eradication efforts. Although P. vivax causes a considerable number of malaria 
cases, its importance has for long been neglected. Vivax malaria can cause severe 
manifestations and death; hence there is a need for P. vivax-directed research. Plants used 
in traditional medicine, namely Artemisia annua and Cinchona spp. are the sources of the 
antimalarial natural products artemisinin and quinine, respectively. Based on these 
compounds, semi-synthetic artemisinin-derivatives and synthetic quinoline antimalarials 
have been developed and are the most important drugs in the current therapeutic arsenal for 
combating malaria. In the Amazon region, where P. vivax predominates, there is a local 
tradition of using plant-derived preparations to treat malaria. Here, we review the current 
P. falciparum and P. vivax drug-sensitivity assays, focusing on challenges and perspectives 
of drug discovery for P. vivax, including tests against hypnozoites. We also present the 
latest findings of our group and others on the antiplasmodial and antimalarial chemical 
components from Amazonian plants that may be potential drug leads against malaria. 
Keywords: herbal remedy; Plasmodium spp.; antimalarials; drug discovery;  
Amazonian plants 
 
1. Introduction  
In the absence of clinically effective vaccines, prevention and treatment of malaria critically depend 
on prophylaxis and drug-based therapy [1]. However, the number of available antimalarial drugs that 
feature distinct mechanisms of action is low. Also, the rate at which antimalarial drug-resistance is 
emerging and spreading is outperforming the development of new drug entities. This is especially 
worrying given reports of artemisinin-resistant P. falciparum in Southeast Asia [2,3]. 
In the Amazon region, plants are widely used in traditional medicine for the treatment of malaria.  
In 1997, Milliken surveyed the literature on plants used for the treatment of malaria infections, fevers 
and related conditions (headaches, etc.) by the people of the Amazon and Caribbean regions [4].  
He described antimalarial plants that are widely distributed and used throughout the Amazon region 
such as Quassia amara L. and Picrolemma sprucei Hook. f. (Simaroubaceae), Aspidosperma spp. 
Geissospermum spp. (Apocynaceae) and Ampelozizyphus amazonicus Ducke (Rhamnaceae). Recently, 
further works have been published on the antimalarial plants and remedies used by native Amazonian 
groups and local populations [5,6]. Indeed, broad scope surveys of antimalarial plant components 
include many Amazonian plant natural products with proven antiplasmodial activity [7,8]. Many 
traditionally used Amazonian plants have not yet been screened for antimalarial activity and little or 
nothing is known about their chemical composition thus making them interesting starting points for 
research on new antimalarials. 
In this review we highlight the potential of Amazonian plants as sources of prospective drug leads 
against malaria, focusing on the findings of our drug discovery group based in Manaus (Amazonas 
State, Brazil) and including important findings of other groups. Specifically, isolated compounds of 
known molecular structure from Amazonian plants for which in vitro or in vivo antiplasmodial activity 
has been confirmed, are covered. Despite this, several elegant studies on plant extracts, fractions and 
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compound-enriched fractions have been published by leading research groups in the past decade [9]. 
Also, we discuss the currently available antimalarial drug-sensitivity assays based on P. falciparum for 
screening and drug discovery. We propose that challenges may be addressed and perspectives created 
in P. vivax drug discovery through multidisciplinary research by laboratories located outside and 
within the Brazilian Amazon. Specifically, in the Brazilian Amazon there is a diversity of medicinal 
plants that is traditionally used to treat P. vivax and P. falciparum infections. Additionally,  
malaria-infected patients have access to hospitals with adequate facilities and personnel where 
molecular, genetic and screening studies may be performed. 
2. Malaria Drug Resistance: Urging the Discovery and Development of New Drugs 
Resistance to antimalarial drugs has been described for three of the five species of human malaria 
parasites, P falciparum, P. vivax and P. malariae [10]. Resistance of P. falciparum to chloroquine 
(CQ), the most promising antimalarial of the 20th century, was first reported less than twenty years 
following its widespread use, with the first reports of resistance originating from South America and 
Southeast Asia at the end of the 1950’s [11,12]. Since then, the spread of CQ-resistance has been 
unrelenting, and currently, CQ-resistance is almost synonymous with P. falciparum [10]. In response 
to CQ-resistance, antifolate combination drugs were introduced. The best known and most widely used 
is the combination of sulfadoxine and pyrimethamine (SP) the latter being a well-known antimalarial 
drug often used on its own. However, pyrimethamine use had already selected resistant P. falciparum 
parasites within one year of its introduction [13]. SP combination therapy was introduced in the 1960’s 
but resistant parasites quickly appeared in Southeast Asia, and spread rapidly to Africa [14]. 
Failure of P. falciparum clinical treatment resulting from parasite resistance to all current antimalarial 
drugs has placed the new generation of drugs, called artemisinin-based combination therapies (ACTs) 
at the forefront of malaria control programs [15]. The rationale for ACTs is to combine a fast-acting 
drug (artemisinin (ART) derivative), with a partner drug with long half-life, such as mefloquine, 
amodiaquine, piperaquine, pyrimethamine/sulfadoxine or lumefantrine, in order to achieve rapid and 
effective parasite clearance and to avoid the development of resistance to ART [16]. However, 
resistance to the partner drug is common, and decreased efficacy to ART derivatives themselves due to 
resistance is already emerging [3]. The development of resistance mutations may be a rare occurrence; 
a spontaneous mutation may occur only once in several million parasites. Nevertheless, once it has 
occurred, it can be selected and disseminated. Consequently, new chemical entities that may overcome 
the mechanisms of resistance to currently used antimalarial drugs are in urgent demand. 
3. Amazonian Plants: Sources of New Antimalarial Drugs Leads 
A pioneer attempt to apply the scientific method to study the pharmaceutical properties of the plants 
from Amazonas State, Brazil was performed by the physician and naturalist Alfredo da Matta [17], 
whose work is still a valuable reference and starting point to research in the field. As expected in a 
place with such a high biodiversity, many others have been following his path, by exploring the plants 
used with medicinal purposes by the native communities [18–20]. Among the rural and riverine 
populations that inhabit the region, a great variety of plant families, such as Fabaceae, Arecaceae, 
Zingiberaceae and Lamiaceae, have been used to prevent and treat a wide variety of symptoms and 
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diseases [19,20]. The recent discovery of plants with considerable antibacterial activity [21,22] and the 
repellent, larvicidal and mosquitocidal properties of plant essential oils and extracts are useful for the 
control of mosquito vectors of malaria and other tropical diseases and demonstrate the potential of the 
regional plant biodiversity [23,24] as source for new active compounds, much of which has yet to  
be explored.  
Plants produce useful chemicals for control and treatment of Plasmodium spp. that cause human 
malaria [25]. Historically, quinine is the most important natural product used to treat malaria. Quinine 
is a constituent of the traditionally used bark of Cinchona spp. and was isolated for the first time in the 
early 19th century. Synthetic quinoline antimalarials were developed during the 20th century based on 
knowledge of quinine´s structure [26,27]. In the 1970’s, the natural product artemisinin was isolated 
by Chinese scientists from the traditionally used antimalarial species Artemisia annua L.. Today, 
artemisinin is isolated from A. annua on an industrial scale. Semi-synthetic derivatives containing the 
intact 1,2,4-trioxane antimalarial chromophore moiety are prepared from artemisinin in simple reaction 
sequences [27]. The ACTs that have been introduced in the past two decades contain a synthetic 
quinoline antimalarial (a phytochemical mimic) and an artemisinin derivative (derived directly from an 
isolated phytochemical) [16]. As has been emphasized, traditionally used plants are the sources of the 
most important drugs in the current therapeutic arsenal for combating malaria.  
4. Field Installed Capacity and Recent Findings from the Manaus Drug Discovery Group  
and Others 
Based on the concept that the next generation of antimalarial drugs may also originate from plants 
used in traditional medicine, a group of collaborators from the Tropical Medicine Foundation Dr. 
Heitor Vieira Dourado (FMT-HVD), the Brazilian State-owned Agronomic and Husbandry Research 
Company (Embrapa), the Federal University of Amazonas (UFAM) and the Federal University of Rio 
Grande do Norte (UFRN) under the leadership of the National Institute for Amazon Research’s 
(INPA’s) Laboratory of Amazonian Active Principles (LAPAAM) has focused on studies on the 
chemical composition and biological activity of antimalarial plants from the Amazon. Table 1 
summarizes information on the chemical composition of plants from the Amazon region. 
Several antimalarial phytochemicals may be isolated on gram or multi-gram scales thus potentiating 
their pharmacological study. The quassinoids neosergeolide and isobruceine B (Figure 1) have each 
been isolated from the stems and roots of the caferana plant (Picrolemma sprucei) on gram scales using 
a multi-stage extraction, chromatography and recrystallization sequence [28]. In other work,  
4-nerolidylcatechol (4-NC, Figure 1) was readily isolated on a multi-gram scale from the roots of 
Piper peltatum L. (syn. Pothomorphe peltata Miq.) by straightforward extraction-chromatography. 
Interestingly, 4-NC makes up >5% of the dry weight of P. peltatum roots [29] and P. peltatum can be 
cultivated in the Brazilian Amazon where its roots produce ca. 27 kg of 4-NC per hectare [30,31], thus 
allowing the use of 4-NC in industrial applications. 
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Table 1. Amazonian antimalarial plants and their antiplasmodial chemical components.  
Plant species Family Common name Collection place Part used Active component IC50 (μM) Pf strain Source 
Aspidosperma desmanthum  
Benth. ex Müll. Arg. 
Apocynaceae araracanga Brazil bark aspidocarpine 0.019 K1 [29,32] 
Aspidosperma ulei Markgr. Apocynaceae  Brazil root bark uleine, olivacine 1.2–3.7 K1, 3D7, W2 [33–35] 
Aspidosperma vargasii A. DC. Apocynaceae amarelão Brazil bark ellipticine 0.073–0.81 K1, 3D7 [29,33] 
Carapa guianensis Aubl. Meliaceae andiroba Peru seed/flower oil gedunins, an andirobin, 
mexicanolides, phragmalin-type 
limonoids (andirolides) 
2.5–15 FCR-3 [36] 
Moronobea coccinea Aubl. Clusiaceae manniballi French Guiana latex polyprenylated acylphloroglucinols, 
isogarcinol,cycloxanthochymol, 
garcinol 
2.1–37 FcB1 [37] 
Picrolemma sprucei Hook. f. Simaroubaceae caferana Brazil root, stem isobrucein B, neosergeolide 0.002–0.008 K1 [29,38] 
Piper peltatum L. Piperaceae caapeba Brazil root, leaf, 
flowering part 
4-nerolidylcatechol 0.67 K1 [29] 
Quassia amara L. Simaroubaceae quinquina de 
Cayenne 
French Guiana fresh leaf simalikalactone D, simalikalactone E 0.010–0.068 FcB1, F32, 
W2 
[39,40] 
Rheedia acuminata (Ruiz & 
Pavon) Planchon & Triana 
Clusiaceae cerillo, botoncillo, 
caraño 
French Guiana root bark prenylated xanthones, polyprenylated 
acylphloroglucinols 
3.2–15 FcB1 [37] 
Simaba orinocensis Kunth Simaroubaceae  Peru root bark orinocinolide, simalikalactone D 0.0063–0.018 D6, W2 [41] 
Tabebuia incana A.H. Gentry Bignoniaceae pau d´arco Brazil bark 5 & 8-hydroxy hydroxyethyl 
naphtho[2,3-b]furan-4,9-diones 
0.67 FcB2 [42,43] 
Tachia grandiflora Maguire & 
Weaver 
Gentianaceae caferana Brazil leaf amplexine (djalonenol) 35 W2 [44,45] 
Tapirira guianensis Aubl. Anacardiaceae piojo French Guiana bark cyclic alkyl polyols 4.7–5.4 F32, FcB1 [46] 
Zanthoxylum. rhoifolium Lam Rutaceae tachuelo French Guiana trunk bark avicine hydroxide, nitidine hydroxide, 
fagaridine 
<0.27–38 FCB1 [47] 
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Figure 1. Molecular structures of antiplasmodial substances found in Amazonian plants 
exhibiting submicromolar IC50 values against Plasmodium falciparum in vitro and/or 
significant in vivo activity in rodent malaria models.  
 
Hyphenated and other analytical methods have been used to determine isobrucein B and 
neosergeolide in caferana (Picrolemma sprucei) infusions [28,48], 5 and 8-hydroxy-2-(1-hydroxy- 
ethyl)naphtho[2,3-b]furan-4,9-dione concentrations in pau d´arco (Tabebuia incana A.H. Gentry) bark 
infusions[42] and 4-NC in Piper peltatum root infusions [30]. UPLC-ESI-MS analysis of the bark 
infusions of 8 Aspidosperma spp. from Manaus, Brazil revealed that only A. vargasii contained 
ellipticine and 2-methyl-1,2,3,4-tetrahydroellipticine [49]. 
LAPAAM in collaboration with others has been actively screening plant extracts for antimalarial 
activity. Since 2007, in vitro testing for antimalarial activity by LAPAAM/FMT-HVD has been based 
on direct counting the number P. falciparum in at least 1,000 erythrocytes on thick blood smears using 
optical microscopy. Several methods (ELISA and tritiated hypoxanthine) are being adopted by INPA 
to increase screening capacity of plant extracts in the future. Several infusions prepared from 
carapanaúba tree (Aspidosperma spp.) bark collected in the region around Manaus exhibited strong  
in vitro inhibition against Plasmodium falciparum K1 strain [32]. In other work, MeOH extracts of 
acariquara branca (Geissospermum argenteum) from Roraima State were also active (IC50 = 4.6 μg/mL) 
against the K1 strain of P. falciparum in vitro. However, acariquara vermelha (Minquartia guianensis) 
extracts were inactive (IC50 > 50 μg/mL) [50]. CHCl3 fractions obtained from root MeOH and leaf 
EtOH extracts of the caferana plant (Tachia grandiflora Maguire & Weaver) inhibited P. falciparum 
(IC50 = 11 and 36 μg/mL, respectively). Root infusions (500 mg/kg/day) of T. grandiflora administered 
4-nerolidylcatechol
aspidocarpine ellipticine isobruceine B
neosergeolide nitidine hydroxide
olivacine orinocinolide simalikalactone D
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orally inhibited (45%–59% inhibition) Plasmodium berghei in infected mice [44]. EtOH and H2O root 
extracts and piceatannol and chrysophanol isolated from roots of the mari-mari-da-terra-firme  
(Cassia spruceana Benth.) [31] were inactive against the K1 strain of P. falciparum [51]. Infusions of 
Artemisia annua cultivated in different Amazonian ecosystems and in another region of Brazil strongly 
inhibited the K1 and 3D7 standard strains and Amazonian field isolates of P. falciparum [33]. 
Several of the isolated phytochemicals in Table 1 and derivatives of these natural compounds 
exhibit significant in vitro and in vivo antimalarial activity. In a seminal publication by our group, the 
indole alkaloids aspidocarpine (Figure 1, IC50 = 19 nM) and ellipticine (IC50 = 73 nM), the quassinoid 
neosergeolide (IC50 = 2.0 nM) and 4-NC (IC50 = 0.67 μM) significantly inhibited the K1 strain of  
P. falciparum [29]. Neosergeolide (Table 1) is toxic to human leukemia cells in vitro but is not  
toxic to normal cells [52]. The cytotoxicity parameters of neosergeolide and isobrucein B against 
normal human cells requires further evaluation. Semi-synthetic derivatives 12-acetylneosergeolide  
(IC50 = 0.22 μM) and 1,12-diacetylisobrucein B (IC50 = 37 μM) were much less active in vitro against 
the K1 strain of P. falciparum than neosergeolide (IC50 = 7.9 nM) and isobrucein B (IC50 = 2.1 nM) 
from which these derivatives were prepared [28].  
Other important natural products from Amazonian plant sources are also presented in Table 1. One 
of the most significant is the quassinoid simalikalactone D which has been isolated from  
Simaba guianensis, S. orinocensis and Quassia amara among other species of Simaroubaceae. Its 
antiplasmodial activity was first described in 1993 and it was repeatedly shown to present high 
antiplasmodial activity against Plasmodium falciparum strains [53]. Simalikalactone D was also found 
to have a median effective dose (ED50) of 3.7 mg/kg/day against the rodent malaria parasite 
Plasmodium yoelii yoelii, highlighting its therapeutic potential in vivo [39].  
In other work, limonoids from Carapa guianensis have been shown to have significant in vitro 
antiplasmodial activity against P. falciparum (Table 1), with no selective toxicity against mouse 
mammary tumor cells [36]. The cytotoxicity of these limonoids should be studied further against 
normal human cell lines. Furthermore, given the in vitro and in vivo antimalarial potential 
demonstrated by the limonoid gedunin and its semi-synthetic derivatives, it is important to study the 
activity of C. guianensis gedunin structurally-related isolates in in vivo rodent malaria models. 
The significant in vitro antiplasmodial activity of ellipticine (Figure 1) against P. falciparum has 
been independently confirmed [45]. Also, some simple derivatives of ellipticine exhibit greater in vitro 
activity than ellipticine against P. falciparum [54]. At LAPAAM, derivatives of ellipticine have been 
prepared by direct reactions on ellipticine, however none of these simple ellipticine derivatives 
exhibited greater in vitro inhibition against P. falciparum than ellipticine itself [49]. In a comparative 
study, we found that ellipticine (IC50 = 0.35–0.81 μg/mL) exhibited greater in vitro activity against the 
K1 and 3D7 strains of P. falciparum in general than its natural structural isomer, the indole alkaloid 
olivacine (Figure 1IC50 = 1.2–1.4 μg/mL) and greater in vitro activity than the indole alkaloid 
cryptolepine (IC50 = 0.80–0.91 μg/mL) [33]. Cryptolepine exhibited elevated in vitro toxicity to 
murine macrophages, whereas ellipticine and olivacine exhibited low toxicity to macrophages and 
selectivity indices >2800. Also, ellipticine (10 mg/kg/day) administered orally or subcutaneously for  
4 days was the most active compound tested. It significantly inhibited P. berghei in mice (inhibition of 
70%–77% versus non-treated controls) and led to mean survival times (MST) of 27–29 days for 
infected mice. At 50 mg/kg/day, ellipticine exhibited comparable in vivo activity to that of the positive 
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control substance chloroquine. Olivacine administered orally was also a highly effective inhibitor of  
P. berghei in mice at ≥50 mg/kg/day providing long MSTs [33]. Ellipticine, olivacine and similar 
highly planar antiplasmodial compounds may inhibit P. falciparum growth through a parasite-specific 
mechanism-involving blockage of the formation of hemozoin (malaria pigment) through formation of 
stable complexes with heme in the parasite digestive vacuole [55]. We believe that ellipticine and 
related structural isomer olivacine may be important prototypes for the development of a new class of 
indole alkaloid antimalarials. More derivatives and analogs of ellipticine should be screened for  
in vitro and in vivo antiplasmodial activity to establish SAR parameters and optimal structures. 
We further investigated the in vitro and in vivo antimalarial activity of 4-NC and also that of  
semi-synthetic derivatives of 4-NC. We characterized their activity against the K1 (IC50 = 1.9 μM) and 
3D7 (IC50 = 6.7 μM) strains (chloroquine resistant and non resistant strain, respectively) and two 
Amazonian field strains (IC50 = 0.16–2.6 μM) of P. falciparum in vitro and against P. berghei in mice. 
In vivo suppression of P. berghei in the 4-day suppressive test was observed by oral administration 
(60%–63% on days 5 and 7 after infection) and by subcutaneous administration (61% on day 7 after 
infection) at doses of 600 mg/kg/day. Also, despite low activity against P. berghei in vivo, after 
ingesting 4-NC, the blood serum of healthy mice was quite active in vitro against P. falciparum [56]. 
O-mono and O,O-disubstituted semi-synthetic derivatives of 4-NC were prepared and found to inhibit 
(IC50 = 0.67–23 μM) the K1 strain of P. falciparum in vitro [38]. These derivatives are more stable 
than 4-NC and exhibit significant antioxidant activity [57]. Importantly, the O,O-diacetyl derivative of 
4-NC at oral doses of 10–25 mg/kg/day in the 4-day suppressive test inhibited P. berghei in  
mice by 67%–70% on days 5 and 7, making this derivative ca. 60 times more active than 4-NC  
(Rocha e Silva, Pohlit et al. unpublished data). Many terpenes from plants exhibit activity against 
Plasmodium spp. [25,58] and it is believed that the inhibition by 4-NC and its derivatives is due in part 
to the 15 carbon terpene nerolidyl side-chain common to these compounds (and the antioxidant 
properties of 4-NC and derivatives). There is experimental evidence that O,O-diacetyl 4-NC, like 
many terpenes found in plants, inhibits the synthesis of terpenoid-containing metabolites in 
Plasmodium falciparum (Rocha e Silva, Katzin, Pohlit et al. unpublished data). In the future, more 
derivatives of 4-NC should be synthesized on gram-scales for evaluation of their in vivo antimalarial 
properties in rodent models, as well as toxicological evaluation necessary for further development. 
In conclusion, we envisage that the plant-derived compounds highlighted above hold great promise 
as effective antimalarials. However, from a drug development perspective there are several gaps that 
need to be addressed before these compounds are considered for clinical development. Further studies 
on their pharmacokinetic properties, namely on absorption, distribution, metabolism, excretion and 
toxicity (ADMET) are desirable in order to best understand the steps required for chemical 
modifications towards the synthesis of analogues with improved properties. The synthesis of analogues 
with enhanced efficacy would also benefit from in-depth studies on the mechanisms of action of these 
compounds. This information would provide important biochemical clues about drug-target affinities, 
which would pave the way for the chemical modifications required for improved potency. The route of 
drug administration in vivo should be considered more often, as there may be variable pharmacokinetic 
outcomes that will impact on the drug’s efficacy depending on the drug’s entry route. Finally, if the 
above parameters are carefully articulated it may be possible and highly desirable, that the in vivo 
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potency of these compounds in experimental models may improve by 10 to 100-fold, making them 
serious candidates for the next steps of drug development. 
5. New Generation Antimalarials: Desirable and Essential Characteristics 
New antimalarial drug leads should be active against all known malaria parasites that infect humans 
(P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi) [1,59]. Differences in the biology and 
life cycles of these species can make this a challenging requirement. New drugs should selectively 
affect Plasmodium spp. while exhibiting tolerable toxicity profiles in humans. Preferably, these 
compounds should target Plasmodium spp. via parasite-specific modes of action involving molecular 
targets and organelles found exclusively in these protozoans [60].  
Many common antimalarials were developed to be effective against blood stages of  
Plasmodium spp. New antimalarial drug leads should ideally be active against blood stages of diverse 
Plasmodium spp. and block transmission of gametocytes of Plasmodium spp. from humans to female 
Anopheles spp. mosquitos (malaria vectors) during blood meals (transmission-blocking activity). Also, 
new chemical entities are desirable that inhibit Plasmodium spp. development prior to or in the liver 
stage (prophylaxis) [1]. 
6. Drug Discovery for P. falciparum: The Path to Appropriate Drug-Sensitive Assays 
The first in vitro test to assess P. falciparum drug-sensitivity was developed in 1968 by  
Rieckmann et al. [61] and consisted in evaluating parasite development from early ring stage to mature 
schizonts. After 24 h of incubation with or without drugs (controls), schizonts were counted in relation 
to the total number of erythrocytes on thick blood smears prepared from the cultured samples [61]. 
This technique known as ‘macrotest’ was capable of distinguishing between chloroquine-sensitive and 
resistant parasite isolates [61]. The schizont maturation test was improved after the establishment of 
the continuous culture in 1976 and the ‘microtest’ developed still remains one of the most common 
techniques for the assessment of drug sensitivity in vitro [62].  
This schizont maturation assay is relatively simple to perform. It requires no expensive equipment. 
It is, however, a labor-intensive procedure and it needs highly trained microscopists [63]. Importantly, 
this test might also result in misinterpretation of data, as drugs that delay parasite growth might give 
the same results as drugs that completely inhibit the parasite development [63]. 
Soon after the introduction of continuous in vitro cultivation of P. falciparum over 30 years  
ago [64], several methodologies were developed to assess P. falciparum growth in vitro. Later, 
standardizing of antimalarial drug screening was achieved. Typically, synchronized parasites at ring 
stage are cultured in the presence of different concentrations of test compound or medium (control). 
After one schizogonic cycle (48 h), parasite growth is determined by different methods and IC50 values 
can be assessed by linear regression analyses of the linear segments of the dose-response curves. 
Alternatively, unsynchronized cultures or more hours of incubation can be employed [63]. 
The oldest and also the most low cost method for assessment of Plasmodium falciparum growth  
in vitro is counting giemsa-stained parasites by light microscopy (the World Health Organization 
standard method). Although simple, this technique is time-consuming and relies on well-trained 
microscopists. It allows for the testing of only a small number of compounds in a given period of time. 
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To overcome those limitations, tritiated hypoxanthine uptake by parasites has been widely employed [65]. 
Hypoxanthine is taken up by the parasite as part of purine salvage and DNA synthesis that are essential 
for parasite development and multiplication. Although highly reliable, this standard method is 
expensive and uses radioactive materials with limited availability, safety, and with a strict disposal 
regulation in mostly developing countries [63,66]. 
P. falciparum development can also be determined by means of the enzymatic activity of pLDH 
(parasite lactate dehydrogenase). pLDH is a terminal enzyme in the glycolysis pathway of the malaria 
parasite. In the pLDH assay, nitroblue tetrazolium is reduced forming a blue formazan product that can 
be measured by spectrophotometry [67]. This assay requires initial parasite densities of 1%–2% and 
therefore, its use is limited [63]. A new pLDH-based assay that measures pLDH levels in a double-site 
enzyme-linked LDH immuno-detection (DELI) assay has been developed. This method is considered 
to be more sensitive [68] than previous methods and therefore is applicable in field conditions. 
Another ELISA-based test relies on the measurement of a histidine and alanine-rich protein produced 
by P. falciparum in the course of its growth and multiplication (HRP2 assay) [69]. The HRP2 assay 
uses a longer culture time than most other assays (72 h instead of 48 h) and parasite growth is assessed 
by measuring the production of HRP2 in a simple, commercially available, double-site sandwich, 
ELISA test kit or essentially any ELISA that is specific to HRP2. 
Many nucleic acid dyes (SYBR Green I, YOYO-1, propidium iodide, acridine orange, hydroethidine, 
Hoechst, DAPI) have been used to assess antimalarial activity of a variety of compounds. These 
methods take advantage of the fact that human erythrocytes lack DNA and RNA [66]. Many methods 
are based on the use of the nucleic acid dyes and, have now been used in high throughout put screening 
(HTS). These methods vary from a simple fluorescence-based parasite proliferation assay [70] to a 
nuclear dye-based high- throughput confocal imaging assay [71]. Flow cytometry is another method 
that uses nucleic acid dyes and has the advantage that appropriate gating can also allow one to 
distinguish different parasite erythrocytic stages [72,73]. Transfected parasites expressing nucleic acid 
dyes appear to be a useful model for drug screening despite the greater complexity of this method. 
Green fluorescent protein (GFP)-recombinant Plasmodium parasites have been successfully used in 
antimalarial screening [74]. Aside from assays using nucleic acid dyes, transfected parasites expressing 
firefly luciferase are another approach for assaying antimalarial drugs. This method generates similar 
sensitivity results to radiolabeled hypoxanthine uptake [75,76]. 
Lastly, to accelerate drug discovery we have recently established a high-throughput high-content 
assay to monitor the intraerythrocytic asexual cycle of P. falciparum. The assay consists of imaging a 
synchronized population of parasites during the erythrocytic cycle and determining through the size of 
fluorescently labeled organelles the developmental age of the parasite. An automated algorithm 
analyzes the images, differentiating between rings, trophozoites and schizonts. This method allows for 
high throughput screening in an unbiased way. It permits the determination of the stage(s) in the 
erythrocytic cycle in which the drug is active. It is now being used to investigate the mechanism of 
action of novel antimalarials (Freitas Junior and Ayong, unpublished data).  
It is important to note that the in vitro techniques based on P. falciparum cultures do not provide 
information on potential in vivo metabolism of phytoconstituents that may be required as an activation 
step of prodrug antimalarial substances. Also, pharmacodynamic, pharmacokinetic and toxicologic 
data are not forthcoming from in vitro studies. Phytoconstituents exhibiting promising in vitro 
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antimalarial activity must therefore be evaluated for in vivo antimalarial activity against P. berghei,  
P. chabaudi, P. yoelii or other rodent or animal models of malaria [77]. In vivo studies are sometimes 
difficult to perform given that larger quantities of isolated natural products are frequently not available. 
Also, government restrictions adopted in many countries to avoid a deliberate use of a large number of 
animals are also a factor to be taken in consideration. However, in vivo studies are essential for the 
development of antimalarial drugs from phytochemicals. 
7. Plasmodium vivax Malaria: Neglected and Misinterpreted 
Plasmodium vivax threatens 2.48 billion people worldwide and infects between 130 and  
435 million people per year [78,79]. P. vivax has some characteristics that make it harder to control 
than P. falciparum, including the existence of dormant liver forms (hypnozoites) that cause relapses 
and the relatively early presence of circulating gametocytes [80]. Accordingly, P. vivax is becoming 
proportionately a more common cause of malaria in some areas where falciparum malaria control has 
been strengthened [81–83]. In Brazil, for example, vivax malaria became predominant around 1990, 
when control measures were intensified [84]. In 2011, Brazil has reported more than 247 thousand 
malaria cases (due to P. vivax, P. falciparum and P. malariae), with 87% of them attributed to  
P. vivax [85]. 
The dogma that classified P. vivax infection as a benign disease is now largely discredited. This is 
due to increasing reports of severe disease caused by this parasite combined with reassessment of the 
importance of the morbidity and mortality associated with this parasite to public health. Indeed, there 
are a great number of studies focusing on severe manifestations of P. vivax worldwide [86–100].  
This former misconception has contributed to long-term neglect of P. vivax infections. One of the 
consequences of this neglect has been that little effort towards research and development of new  
anti-P. vivax drugs has been made [101–103]. 
Treatment of P. vivax infections in most endemic areas is based on chloroquine (CQ), used alone or 
in combination with primaquine. The latter is the only approved antimalarial drug that acts on 
Plasmodium spp. liver stages (hypnozoites), preventing relapses [85]. P. vivax CQ-resistance was 
reported in Papua New Guinea in 1989 [104], almost thirty years after the emergence of CQ-resistance 
in P. falciparum [105]. To date, there is clear evidence of the existence of CQ-resistant P. vivax in 
many other countries, including those of northern South America [106–108]. The high prevalence of  
CQ-resistant P. vivax in some areas [106,109] has been hypothesized as an important contributor to the 
high risk of severe vivax disease [88] and contributes to the overall morbidity. 
8. Drug Discovery for P. vivax: The Next Step Forward 
P. vivax infection is a neglected disease for which few drug susceptibility studies have been 
performed [103]. Indeed, drug susceptibility assays are a complicated undertaking as long term in vitro 
culture systems for the erythrocytic forms of this parasite have not yet been developed. This 
technological barrier precludes the implementation of P. vivax drug discovery programs. Efforts 
towards discovery, characterization and proper validation of P. vivax drug targets are significantly 
hampered. Knowledge of these molecular targets is necessary for the development of specific 
biochemical assays. Thus, medium to large scale screening campaigns of compound libraries against 
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whole P. vivax parasites are not possible. Such campaigns would require robust and reproducible 
assays using lab-adapted P. vivax parasites. From the clinical drug development perspective, major 
candidate molecules against P. falciparum have been proposed to be tested first in proof-of-concept 
studies using P. vivax-infected patients, since this infection is considered to be more benign and 
therefore, phase II studies would not submit patients to higher risk of severe disease. However, the 
increase in the report of severe vivax cases worldwide makes this approach somehow questionable.  
In this scenario, the pragmatic solution is to continue to use P. falciparum as a surrogate model for 
vivax antimalarial drug discovery (see section on drug-sensitivity assays). Historically, clinical use of 
the same drugs to treat all human malarias has provided experience that in spite of biological 
differences, P. falciparum is a suitable model for in vitro drug testing and drug discovery for P. vivax 
malaria. However, reports in the past years have challenged this belief. For example, it has been 
suggested that P. vivax is intrinsically resistant to antifolates [110], although this has been contested by 
more recent data [111]. Russell et al. demonstrated that P. vivax trophozoites are considerably more 
resistant to chloroquine than P. falciparum trophozoites in ex vivo maturation assays, even when 
parasites were sampled from patients from endemic areas associated with reasonable chloroquine 
therapeutic sensitivity [112]. Additionally, experimental data suggest that mechanisms of resistance to 
chloroquine differ between P. falciparum and P. vivax [111,113,114]. 
The ex vivo schizont maturation test has been successfully employed over the past years to assess 
levels of antimalarial resistance and test novel drug candidates against P. vivax [115–118]. This assay 
consists of visually monitoring the erythrocytic development of ring and young trophozoites into mature 
schizonts, and drugs that are able to inhibit the maturation process in a dose-dependent manner are 
considered active against P. vivax. However, the test results can be influenced by the initial blood stage 
composition and the speed of maturation of the clinical isolate [112,116]. In any case, though it is not a 
high throughput method, the 48 h short-term in vitro culture of P. vivax may serve at the moment as a 
reasonable screening tool in order to evaluate antimalarials against this species’ blood stages.  
9. Hypnozoite Drug Tests: The Greatest Challenge 
To achieve malaria eradication it is paramount to have drugs effective against hypnozoites, the 
mysterious dormant liver stage that causes relapses in P. vivax and P. ovale malaria [119]. To date, 
few in vitro hypnozoite assays have been developed for both P. vivax and the monkey malaria parasite 
P. cynomolgi [120–123]. However it remains to be shown whether these assays can be used for routine 
drug discovery as they are technically challenging, and can only be carried out in facilities where 
insectaries are available. Also, in the case of hypnozoites, as opposed to blood stages, the use of  
P. falciparum as surrogate model is unsuitable, as it cannot produce hypnozoites. In the Amazon, in 
some research centers, the possibility of inducing experimental P. vivax in vitro liver stage infection 
(concomitant availability of infected patient-derived gametocytes and insectaries with An. aquasalis in 
Manaus, Brazil or An. albimanus in Cali, Colombia) paves the way for future studies, which are not 
possible outside the endemic area.   




In the future, we believe that several substances derived from Amazonian plants could be evaluated 
for in vitro activity against clinical samples of P. vivax in limited culture and for transmission-blocking 
and prophylactic activity of P. berghei in different laboratory models. As we mentioned, ellipticine, its 
derivatives and 4-nerolidylcatechol derivatives have potential as lead compounds for the development 
of new antimalarial drugs. 
P. vivax has tended to be neglected despite recent reports indicating that severe vivax malaria may 
be underestimated. Moreover, there is evidence that P. vivax has developed resistance to chloroquine, 
sulfadoxine + pyrimethamine [124] and primaquine [125]. There is now a priority to also put emphasis 
on P. vivax-directed research. Thus, the use of novel screening technologies, most notably image-based 
assays that can distinguish between the live and dead parasites and between rings, trophozoites and 
schizont stages (Freitas-Junior and collaborators, unpublished data), and cytometry-based high-content 
screening with probes that can identify and quantitate mature blood stages in low parasitemia [126–128] 
hold promise if they can be coupled to the schizont maturation test. Recent work featuring an 
automated high content screening assay that measured parasite size and consequently schizont growth 
and maturation of P. yoelii liver stage [129] demonstrated that this approach is viable. A rational 
approach, given the variable nature of the ex vivo maturation test, would be to have antimalarial drugs 
tested against lab adapted P. falciparum strains to select only compounds able to block the 
intraerythrocytic development and maturation of asexual forms. In this way, the likelihood of finding 
compounds active against clinical isolates in ex vivo maturation tests would increase. Although more 
challenging, similar strategies could be employed to selected drug leads in P. vivax-infected hepatocytes.  
11. Concluding Remarks 
Traditionally-used Amazonian plants are important for the discovery of new antimalarial leads against 
P. falciparum and P. vivax. The success of this drug discovery effort depends on the availability of 
increased capacity screening facilities in malaria endemic areas, which in turn are very often  
resource-limited areas. Therefore, solid drug discovery programs for P. vivax depend on the 
establishment of multidisciplinary research networks involving several institutions and expertises. 
Also, considerable investments are needed to equip laboratories in endemic regions to develop novel 
assays that can enable the screening of novel compounds against the P. vivax parasite. 
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